PDF | On Jan 1, , E.M. Ginzler and others published Aspreva Lupus Management Study (ALMS): Maintenance Results. [abstract]. *Members of the Aspreva Lupus Manage- ment Study (ALMS) Group are listed in the Supplementary Appendix, available at The study group underwent repeat randomization in a ratio. A total of patients were randomly assigned to maintenance treatment ( to a renal response to treatment and in preventing relapse in patients with lupus (Funded by Vifor Pharma [formerly Aspreva]; ALMS number, NCT).

Author: Gokasa Nazahn
Country: Pacific Islands
Language: English (Spanish)
Genre: Relationship
Published (Last): 18 September 2013
Pages: 398
PDF File Size: 14.50 Mb
ePub File Size: 19.72 Mb
ISBN: 918-9-94762-707-4
Downloads: 22073
Price: Free* [*Free Regsitration Required]
Uploader: Tazilkree

Sequential therapies for proliferative lupus nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited.

Author information Article notes Copyright and License information Disclaimer.

Recent studies have suggested that mycophenolate mofetil MMF may offer advantages over intravenous cyclophosphamide IVC for the treatment of lupus nephritis, but these therapies mnagement not been compared in an international randomized, controlled trial.

The relationship between cancer and medication exposures in systemic lupus erythematosus: The h urine collections were obtained at baseline and every 4 wk thereafter until completion of the wk induction phase.

A total of 14 patients died during the study: Articles from Journal of the American Society of Nephrology: There were no statistically significant differences between the scores of each treatment group on any of the secondary efficacy end points Table 3.

The mean duration of asprevz was There were more deaths in the MMF group, contrasting with previous trials.

An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a year period. Focal proliferative class III and diffuse proliferative class IV lupus nephritis are mediated by immune and inflammatory mechanisms responsive to immunosuppression and antiinflammatory therapy, and preferred therapy has generally been with a combination of prednisone plus cyclophosphamide based upon a landmark study from the NIH.


Impact of the ALMS and MAINTAIN trials on the management of lupus nephritis.

Although meta-analyses of smaller studies 17 — 19 have suggested that more patients respond to MMF than to IVC, results from the large and racially diverse population of this study indicate that these drugs in combination with prednisone stufy similar efficacy in short-term induction therapy. Six randomly assigned patients one in the MMF group and five in the IVC group were excluded from the safety analysis because they received no study drug.

The results of this study may support the clinical impression that the efficacy of IVC varies between racial and ethnic groups and that IVC is less effective in patients of Managemenh or Hispanic descent. Oral MMF was given twice daily, titrated from 0.

Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis. The reasons for withdrawal before 24 wk in both groups are described in Table 2. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus SLE as a model for the study of ethnic disparities in SLE. Mycophenolate xspreva vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis.

An independent Data and Safety Monitoring Board, comprising two physicians and one biostatistician, was convened every 3 mo to review lupjs data on an ongoing basis.


Any patient who did not complete the wk induction phase for any reason or who sapreva pulse methylprednisolone therapy for major renal or extrarenal flare was classified as a nonresponder. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Detailed inclusion and exclusion criteria are given in Supplemental Table 2.

Notes Published online ahead of print. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Randomization and Interventions Patients were randomly assigned 1: We did not detect ,anagement differences between the MMF and IVC groups with regard to rates of adverse events, serious adverse events, or infections.

Impact of the ALMS and MAINTAIN trials on the management of lupus nephritis.

Clin J Am Soc Nephrol 2: Lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. This study was sponsored by the Aspreva Pharmaceuticals Corporation as part of the Roche-Aspreva collaboration agreement. Patients were randomly assigned 1: Data for the lupks population was supportive of that observed for the intention-to-treat population; the primary efficacy end point was achieved by 86 Nephrol Dial Transplant During 24 wk, increased malignancy risk or gonadal toxicity with IVC was not expected.